Orexigen Therapeutics Inc (OREX) Financial Statements (2024 and earlier)

Company Profile

Business Address 3344 N. TORREY PINES CT.
LA JOLLA, CA 92037
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2017
MRQ
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 103,993214,011205,537176,996137,403
Cash and cash equivalents 92,494155,422104,24398,12178,332
Short-term investments 11,49958,589101,29478,87559,071
Restricted cash and investments 90,005    
Receivables 1,1026,8282,571  
Inventory, net of allowances, customer advances and progress billings 23,19310,8021,198
Inventory 23,19310,8021,198  
Prepaid expense and other current assets1,491
Deferred tax assets   547  
Other undisclosed current assets 6,1682,2541,4731,286 
Total current assets: 224,461233,895211,326178,282138,894
Noncurrent Assets
Property, plant and equipment 1,0441,28485763083
Intangible assets, net (including goodwill) 76,061  
Intangible assets, net (excluding goodwill) 76,061    
Restricted cash and investments 188138177177177
Other noncurrent assets 2,8351,2726211,032
Total noncurrent assets: 80,1282,6941,6551,839260
TOTAL ASSETS: 304,589236,589212,981180,121139,154
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 45,62216,80815,46116,31212,116
Employee-related liabilities   4,6664,7743,960
Accounts payable 15,2106,4854,2434,7873,811
Accrued liabilities 30,41210,3236,5526,7514,345
Business combination, contingent consideration, liability 15,000  
Deferred revenue and credits 4,7389,6138,2293,4293,429
Other undisclosed current liabilities  5,8206,0243,1129,569
Total current liabilities: 65,36032,24129,71422,85325,114
Noncurrent Liabilities
Liabilities, other than long-term debt 12,66382,84177,01535,37538,571
Deferred revenue and credits 5,86382,69176,11435,14338,571
Deferred tax liabilities, net   547  
Other liabilities  150354232 
Business combination, contingent consideration, liability 6,800  
Total noncurrent liabilities: 12,66382,84177,01535,37538,571
Total liabilities: 78,023115,082106,72958,22863,685
Equity
Equity, attributable to parent 57,04433,37822,34441,86275,469
Common stock 1514612310584
Additional paid in capital 698,229653,704574,247556,235512,174
Accumulated other comprehensive income (loss) 4,011215(26)(3)15
Accumulated deficit (645,211)(620,687)(552,000)(514,475)(436,804)
Total equity: 57,04433,37822,34441,86275,469
Other undisclosed liabilities and equity 169,52288,12983,90880,031 
TOTAL LIABILITIES AND EQUITY: 304,589236,589212,981180,121139,154

Income Statement (P&L) ($ in thousands)

9/30/2017
TTM
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Revenues 33,70924,45955,5213,4283,428
Revenue, net 27,91410,5941,292  
Cost of revenue
(Cost of Goods and Services Sold)
 (7,995)    
Gross profit: 25,71424,45955,5213,4283,428
Operating expenses (82,684)(84,512)(86,051)(80,626)(93,667)
Operating loss: (56,970)(60,053)(30,530)(77,198)(90,239)
Nonoperating income (expense) 32,579(7,258)(6,907)(408)292
Investment income, nonoperating   8865147
Other nonoperating income (expense) 32,579(7,258)(6,995)(473)145
Interest and debt expense 18,287(7,446)(7,083)(538)(2)
Loss from continuing operations before equity method investments, income taxes: (6,104)(74,757)(44,520)(78,144)(89,949)
Other undisclosed income (loss) from continuing operations before income taxes (18,287)7,446   
Loss from continuing operations before income taxes: (24,391)(67,311)(44,520)(78,144)(89,949)
Income tax expense (133)(1,376)   
Loss from continuing operations: (24,524)(68,687)(44,520)(78,144)(89,949)
Loss before gain (loss) on sale of properties: (24,524)(68,687)(44,520)(78,144)(89,949)
Net loss: (24,524)(68,687)(44,520)(78,144)(89,949)
Other undisclosed net income (loss) attributable to parent   6,995473(145)
Net loss available to common stockholders, diluted: (24,524)(68,687)(37,525)(77,671)(90,094)

Comprehensive Income ($ in thousands)

9/30/2017
TTM
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss: (24,524)(68,687)(44,520)(78,144)(89,949)
Comprehensive loss: (24,524)(68,687)(44,520)(78,144)(89,949)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 3,7952426,972455(128)
Comprehensive loss, net of tax, attributable to parent: (20,729)(68,445)(37,548)(77,689)(90,077)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: